Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|July 26, 2021
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trialsJason R Westin, Marie José Kersten, Gilles Salles, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
International Journal of Clinical Oncology|June 15, 2026
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trialDai Maruyama, Hideki Goto, Takahiro Kumode, et al.
Blood|October 2, 2004
PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL inductionChun Crowder, Øyvind Dahle, R Eric Davis, et al.
Frontiers in Oncology|November 18, 2014
A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribineKoji Sasaki, Naveen Pemmaraju, Jason R Westin, et al.
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Oncogene|December 17, 2002
The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathwayDemetrios Kalaitzidis, R Eric Davis, Andreas Rosenwald, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
Pageof 18